ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating

A sharp share price drop is reported, with no additional company information disclosed.

What the company is saying

The announcement states that investors in ADMA Biologics, Inc. saw the price of their shares slide over 16% on March 24, 2026, following a report by Culper Research. The announcement encourages investors with losses to contact the firm. No other company information or commentary is provided.

What the data suggests

The only data disclosed is that ADMA Biologics, Inc. shares declined over 16% on March 24, 2026, after a report by Culper Research. No other financial figures or company metrics are provided.

Analysis

The announcement is factual and focused on a realised event: a share price decline of over 16% for ADMA Biologics, Inc. following a report by Culper Research. There are no forward-looking statements, projections, or claims of future benefit. The language is direct and does not attempt to inflate the significance of the event beyond the disclosed numerical fact. No capital outlay or investment is mentioned, and there is no discussion of operational or financial improvements. The only additional claim is an encouragement for investors with losses to contact the firm, which is a standard legal solicitation and not an exaggerated statement. Overall, the narrative matches the evidence provided, with no signs of overstatement or narrative inflation.

Announcement summary

Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) saw the price of their shares slide over 16% on March 24, 2026 following a report by short seller Culper Research. The announcement encourages investors with losses to contact the firm. The event is significant as it highlights a notable decline in share price attributed to the release of the report. The announcement was made in SAN FRANCISCO on April 21, 2026.

Disagree with this article?